Medicinal chemistry of the renin-angiotensin system:
Saved in:
| Format: | Book |
|---|---|
| Language: | English |
| Published: |
Lausanne u.a.
Elsevier
1994
|
| Series: | Pharmacochemistry library
21 |
| Subjects: | |
| Online Access: | Inhaltsverzeichnis |
| Physical Description: | XXVI, 412 S. Ill., zahlr. graph. Darst. |
| ISBN: | 0444820531 |
Staff View
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV010162048 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 950428s1994 ad|| |||| 00||| engod | ||
| 020 | |a 0444820531 |9 0-444-82053-1 | ||
| 035 | |a (OCoLC)488897082 | ||
| 035 | |a (DE-599)BVBBV010162048 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-355 | ||
| 050 | 0 | |a QP609.R38 | |
| 082 | 0 | |a 612 |2 20 | |
| 084 | |a WW 8240 |0 (DE-625)152138:13423 |2 rvk | ||
| 245 | 1 | 0 | |a Medicinal chemistry of the renin-angiotensin system |c ed. by Pieter B. M. W. M. Timmermans ... |
| 264 | 1 | |a Lausanne u.a. |b Elsevier |c 1994 | |
| 300 | |a XXVI, 412 S. |b Ill., zahlr. graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Pharmacochemistry library |v 21 | |
| 650 | 4 | |a Angiotensin converting enzyme - Inhibitors - Therapeutic use | |
| 650 | 4 | |a Angiotensins - Physiological effect | |
| 650 | 4 | |a Angiotensins - Receptors - Antagonists | |
| 650 | 4 | |a Hypertension - Chemotherapy | |
| 650 | 4 | |a Renin - Inhibitors - Therapeutic use | |
| 650 | 4 | |a Renin - Physiological effect | |
| 650 | 0 | 7 | |a Renin-Angiotensin-System |0 (DE-588)4177770-0 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Klinische Chemie |0 (DE-588)4135255-5 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Renin-Angiotensin-System |0 (DE-588)4177770-0 |D s |
| 689 | 0 | 1 | |a Klinische Chemie |0 (DE-588)4135255-5 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Timmermans, Pieter B. |e Sonstige |4 oth | |
| 830 | 0 | |a Pharmacochemistry library |v 21 |w (DE-604)BV001899371 |9 21 | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006748516&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-006748516 | ||
Record in the Search Index
| _version_ | 1804124557577027584 |
|---|---|
| adam_text | PHARMACOCHEMISTRY LIBRARY EDITOR: H. TIMMERMAN VOLUME 21 MEDICINAL
CHEMISTRY OF THE RENIN-ANGIOTENSIN SYSTEM EDITED BY PIETER B.M.W.M.
TIMMERMANS AND RUTH R. WEXLER THE DUPONT MERCK PHARMACEUTICAL COMPANY
WILMINGTON, DE, U.S.A. ELSEVIER - LAUSANNE - NEW YORK - OXFORD - SHANNON
- TOKYO 1994 XV CONTENTS FOREWORD P.B.M.W.M. TIMMERMANS AND R. R.
WEXLER. LIST OF CONTRIBUTORS CHAPTER 1 OVERVIEW OF THE RENIN ANGIOTENSIN
SYSTEM: TARGETS FOR INTERVENTION J.H. LARAGH 1. INTRODUCTION 1 2.
MECHANISMS OF THE RENIN SYSTEM 1 3. THE RENIN-SODIUM PROFILE 3 4.
VASOCONSTRICTION-VOLUME ANALYSIS 5 5. THE RENIN SYSTEM IN ESSENTIAL
HYPERTENSION 6 6. NEPHRON HETEROGENEITY: PATHOLOGY OF ESSENTIAL
HYPERTENSION AT THE RENAL CELLULAR LEVEL? 10 7. RENIN AS A RISK FACTOR
11 8. MODERN PHARMACOLOGY IN THE MANAGEMENT OF HYPERTENSION 15 8.1.
BETA-ADRENERGIC BLOCKERS: THE FIRST ANTI-RENIN SYSTEM AGENTS 15 8.2.
COMPETITIVE ANTAGONISM FOR ANGIOTENSIN II RECEPTORS 17 8.3. CONVERTING
ENZYME INHIBITION 18 9. MODERN, SPECIFIC PHARMACOLOGIC STRATEGY 19 10.
CONCLUSION 22 REFERENCES 23 CHAPTER 2 THE INHIBITION OF THE
RENIN-ANGIOTENSIN SYSTEM AS A THERAPEUTIC MODALITY B. WAEBER, M. BURNIER
AND H.R. BRUNNER 1. INTRODUCTION 27 2. THE RENIN-ANGIOTENSIN SYSTEM 27
XVI 3. ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS 30 4. ACE
INHIBITORS AS TREATMENT OF HYPERTENSION 31 4.1. MODE OF ACTION 31 4.2.
HEMODYNAMIC EFFECTS 32 4.3. ANTIHYPERTENSIVE EFFICACY 32 4.3.1.
ESSENTIAL HYPERTENSION 32 4.3.2. RENOVASCULAR HYPERTENSION 34 4.3.3.
PRIMARY HYPERALDOSTERONISM 34 4.3.4. PHEOCHROMOCYTOMA 35 4.3.5. RENAL
DISEASE 35 4.3.6. PREGNANCY 35 4.4. ANGIOTENSIN CONVERTING ENZYME
INHIBITORS AND ASSOCIATED DISEASES 35 4.4.1. CARDIAC HYPERTROPHY 35
4.4.2. CONGESTIVE HEART FAILURE 35 4.4.3. CORONARY HEART FAILURE 35
4.4.4. CEREBROVASCULAR DISEASE 36 4.4.5. PERIPHERAL VASCULAR DISEASE 36
4.4.6. DIABETES MELLITUS 36 4.4.7. X SYNDROME 36 4.4.8. HYPERLIPIDEMIA
36 5. ANGIOTENSIN CONVERTING ENZYME INHIBITORS AS TREATMENT OF CHRONIC
HEART FAILURE 37 5.1. ROLE OF THE RENIN-ANGIOTENSIN SYSTEM IN CONGESTIVE
HEART FAILURE 37 5.1.1. HEMODYNAMIC EFFECTS 37 5.1.2. QUALITY OF LIFE 38
5.1.3. PHYSICAL PERFORMANCE 38 5.1.4. PROGNOSIS 38 5.1.5. PRACTICAL USE
39 6. ANGIOTENSIN CONVERTING ENZYME INHIBITORS AFTER MYOCARDIAL
INFARCTION 39 7. SIDE-EFFECTS OF ANGIOTENSIN CONVERTING ENZYME
INHIBITORS 40 XVII 8. CONCLUSION 41 REFERENCES 42 CHAPTER 3 ANGIOTENSIN
CONVERTING ENZYME INHIBITORS: NEW CLINICAL APPLICATIONS S. ANDERSON AND
R.E. HERSHBERGER 1. INTRODUCTION 47 2. ACE INHIBITORS AND PROGRESSIVE
RENAL DISEASE 47 2.1. THE PROGRESSIVE NATURE OF RENAL DISEASE 47 2.2.
ROLE OF SYSTEMIC HYPERTENSION 48 2.3. ROLE OF ACE INHIBITORS IN DIABETIC
NEPHROPATHY 50 2.4. MECHANISMS OF RENAL PROTECTION WITH ACE INHIBITORS
52 3. ACE INHIBITORS AND CLINICAL CARDIOVASCULAR DISEASE 54 3.1. ACE
INHIBITORS IN HEART FAILURE: MORTALITY TRIALS 54 3.2. POTENTIAL
MECHANISMS OF THE BENEFICIAL EFFECTS OF ACE INHIBITORS IN HEART FAILURE:
INSIGHTS FROM CLINICAL TRIALS 56 3.3. THE RENIN-ANGIOTENSIN SYSTEM IN
HEART FAILURE 57 3.4. THE VASCULAR RENIN-ANGIOTENSIN SYSTEM 58 3.5. THE
CARDIAC RENIN-ANGIOTENSIN SYSTEM 58 3.6. ACE INHIBITORS FOLLOWING
MYOCARDIAL INFARCTION 59 4. SUMMARY AND FUTURE DIRECTIONS 60 REFERENCES
61 CHAPTER 4 RENIN AND PRORENIN: PROCESSING MECHANISMS D.F. CATANZARO
AND J.E. SEALEY 1. INTRODUCTION 65 2. RENIN AND PRORENIN SYNTHESIS AND
SECRETION 66 3. SORTING BETWEEN REGULATED AND CONSTITUTIVE PATHWAYS 67
4. PRORENIN PROCESSING 68 XVIII 5. SUMMARY AND CONCLUSION 70 REFERENCES
71 CHAPTER 5 RENIN INHIBITOR DESIGN THROUGH MOLECULAR MODELING E.A.
LUNNEY AND C. HUMBLET 1. INTRODUCTION 73 2. DISCUSSION 73 2.1. 3D RENIN
MODEL 75 2.2. P1-P1 SUBSITE 75 2.3. P2 TO P4 CONSTRAINED ANALOGS 82 2.4.
CYCLIZED INHIBITORS 87 2.5. RECENTLY SOLVED ENZYME CRYSTAL STRUCTURES -
RENIN 95 3. CONCLUSION 98 REFERENCES 99 CHAPTER 6 CURRENT STATUS OF
CLINICAL TRIALS ON RENIN INHIBITORS P. VAN BRUMMELEN 1. INTRODUCTION 103
2. EARLY INTRAVENOUS RENIN INHIBITORS 104 3. IMPROVED INTRAVENOUS AND
ORAL RENIN INHIBITORS 105 3.1. CGP 38 560 A 106 3.2. ENALKIREN (A 64662)
107 3.3. REMIKIREN (RO 42-5892) 108 3.4. ES-8891 110 3.5. OTHER NEW
RENIN INHIBITORS 110 4. RENIN INHIBITOR INDUCED CHANGES IN THE RENIN
ANGIOTENSIN SYSTEM 110 4.1. CHANGES IN PRA, ANGIOTENSIN I AND
ANGIOFENSIN II 110 4.2. APPARENT DISSOCIATION BETWEEN CHANGES IN PRA AND
ANGIOTENSIN II.... 111 XIX 4.3. CHANGES IN ACTIVE PLASMA RENIN 111 4.4.
CHANGES IN PLASMA ALDOSTERONE 113 5. PHARMACOKINETICS OF RENIN
INHIBITORS 113 6. THE BLOOD PRESSURE LOWERING EFFECT OF RENIN INHIBITORS
114 6.1. BLOOD PRESSURE EFFECTS NORMOTENSIVE HUMANS 114 6.2. BLOOD
PRESSURE EFFECTS IN HYPERTENSIVE PATIENTS 114 7. RENIN INHIBITOR TRIALS
IN OTHER INDICATIONS 115 8. THE FUTURE OF RENIN INHIBITORS 116
REFERENCES 117 CHAPTER 7 ANGIOTENSIN II RECEPTOR ANTAGONISTS: DESIGN,
SAR AND DEVELOPMENT OF LOSARTAN J.R. PRUITT AND R.E. OLSON 1.
INTRODUCTION 121 2. NONPEPTIDE LEADS 122 3. EARLY NOVEL ANTAGONISTS 123
3.1. PHTHALAMIC ACIDS 124 3.2. PHTHALAMIC ACID ANALOGS 127 4. BIPHENYL
ANTAGONISTS 128 4.1. IMIDAZOLE R2 ANALOGS 129 4.2. IMIDAZOLE R4 ANALOGS
130 4.3. IMIDAZOLE R5 ANALOGS 131 4.4. BIPHENYLCARBOXYLIC ACID ANALOGS
132 4.5. LOSARTAN 135 4.6. R4 PERFLUOROALKYLIMIDAZOLES 137 4.6.1. DUP532
138 4.7. R4 ALKYLIMIDAZOLES 140 4.7.1. SYNTHESIS OF 4-ALKYLIMIDAZOLES
141 4.7.2. DISCUSSION OF BIOLOGICAL ACTIVITY OF DMP 581 AND DMP 811 143
4.8. OTHER IMIDAZOLE-4-SUBSTITUENTS 144 5. BALANCED AT1/AT2 ANTAGONISTS
145 5.1. 4-AMINOMETHYLIMIDAZOLES 146 XX 5.2. ORTFTO-SUBSTITUTED
SULFONAMIDOBIPHENYLMETHYLIMIDAZOLES 148 5.3. EFFECTS OF LARGE
5-SUBSTITUENTS ON THE IMIDAZOLE RING 151 6. CONCLUSION 152 REFERENCES
153 CHAPTER 8 ANGIOTENSIN II RECEPTOR ANTAGONISTS: MOLECULAR MODELING
R.H. BRADBURY, B.B. MASEK, D.A. ROBERTS 1. INTRODUCTION 157 2.
STRUCTURAL COMPARISON OF NONPEPTIDE ANGIOTENSIN II RECEPTOR ANTAGONISTS
WITH ANGIOTENSIN II 159 3. DESIGN OF NONPEPTIDE ANGIOTENSIN II RECEPTOR
ANTAGONISTS 162 4. CONCLUSION 171 REFERENCES 171 CHAPTER 9 NONPEPTIDE
ANGIOTENSIN II RECEPTOR ANTAGONISTS: DESIGN AND SAR OF
IMIDAZOLE-5-ACRYLIC ACIDS R.M. KEENAN, J. WEINSTOCK, J.C. HEMPEL, J.M.
SAMANEN, D.T. HILL, N. AIYAR, D.P. BROOKS, E.H. OHLSTEIN AND R.M.
EDWARDS 1. INTRODUCTION 175 2. DESIGN OF IMIDAZOLE-5-ACRYLIC ACIDS 176
3. EXTENSION OF THE ACID SIDECHAIN 183 4. SAR OF IMIDAZOLE-5-ACRYLIC
ACIDS 184 5. OVERLAY OF SK&F 108566 ON ANGIOTENSIN II 195 6.
PHARMACOLOGICAL PROFILE OF SK&F 108566 197 7. CONCLUSION 200 REFERENCES
200 XXI CHAPTER 10 ANGIOTENSIN II RECEPTOR ANTAGONISTS: NOVEL
HETEROCYCLES S.E. DE LASZLO AND W.J. GREENLEE 1. INTRODUCTION 203 2. ANG
II RECEPTOR SUBTYPES 204 3. DEVELOPMENT OF LOSARTAN AND SK&F 108,566
FROM THE TAKEDA BENZYLIMIDAZOLE LEADS 205 4. THE IMPORTANCE OF
HETEROCYCLIC REPLACEMENTS OF THE IMIDAZOLE IN THE LOSARTAN SERIES . 209
5. NEW HETEROCYCLIC ANTAGONISTS DERIVED FROM LOSARTAN 210 5.1. FUSED
IMIDAZOLES 211 5.1.1. BENZIMIDAZOLES 211 5.1.2. LMIDAZO[4,5-B]PYRIDINES
212 5.1.3. OTHER FUSED IMIDAZOLES 215 5.2. OTHER FIVE-MEMBERED
HETEROCYCLIC ANTAGONISTS 217 5.3. CARBON-LINKED FIVE-MEMBERED RING (AND
FUSED FIVE-MEMBERED RING) HETEROCYCLIC ANTAGONISTS 219 5.4. SIX-MEMBERED
RING HETEROCYCLIC ANTAGONISTS 220 5.5. OTHER SIX-MEMBERED RING
HETEROCYCLIC ANTAGONISTS 222 5.6. OTHER TYPES OF HETEROCYCLIC AND
NON-HETEROCYCLIC ANTAGONISTS 222 6. IN VIVO PROPERTIES OF ATI-SELECTIVE
ANTAGONISTS 226 7. CONCLUSION 227 REFERENCES 236 CHAPTER 11 ANGIOTENSIN
II RECEPTOR ANTAGONISTS: NON-BIPHENYL TETRAZOLES D. MIDDLEMISS AND B.C.
ROSS 1. INTRODUCTION 241 2. HETEROCYCLIC COMPOUNDS 242 2.1. BICYCLIC
HETEROCYCLES 242 2.1.1. INDOLES 242 XXII 2.1.2. BENZOFURANS 246 2.1.3.
BENZOTHIOPHENES 251 2.1.4. BENZOXAZOLES 252 2.2. MONOCYCLIC HETEROCYCLES
252 2.2.1. 5-MEMBERED RING HETEROCYCLES 252 2.2.2. 6-MEMBERED RING
HETEROCYCLES 254 3. CARBOCYCLIC COMPOUNDS 255 3.1. NAPHTHALENES 255 3.2.
CYCLOALKENES 256 4. ALICYCLIC COMPOUNDS 256 4.1. ANILIDES 256 4.2.
ETHERS 258 4.3. BENZAMIDES 259 4.4. ACETIC ACIDS 260 5. COMPOUNDS OF
CURRENT INTEREST 260 5.1. BMS 180560 260 5.2. GR117289 261 5.3. GR138950
263 5.4. GR129085 264 ACKNOWLEDGMENTS 265 REFERENCES 265 CHAPTER 12
HETEROGENEITY OF ANGIOTENSIN RECEPTOR SUBTYPES M. DE GASPARO, S.
WHITEBREAD, S.P. BOTTARI AND N.R. LEVENS 1. INTRODUCTION 269 2. AT1 AND
AT2 SUBTYPES. 271 2.1. DISTRIBUTION AND AFFINITY 271 2.2. ATI ISOFORMS
AND SIGNALLING MECHANISMS : 275 2.3. REGULATION OF THE ATI RECEPTOR
EXPRESSION 277 2.4. AT2 RECEPTOR ISOFORMS AND SIGNALLING MECHANISMS 277
2.5. AT2 RECEPTOR HETEROGENEITY 278 3. THE CYTOSOLIC ANG II BINDING
PROTEIN 279 XXIII 4. THE NUCLEAR BINDING SITE 28 0 5. AT3, A NEW
RECEPTOR? 281 6. SPECIFIC BINDING SITES FOR ANG (3-8) 282 7.
NON-MAMMALIAN ANG II RECEPTORS 282 7.1. AMPHIBIAN ANG II RECEPTORS 283
7.2. AVIAN ANG II RECEPTORS 283 7.3. MYCOPLASMA-RELATED BINDING SITES
284 8. MISCELLANEOUS 285 8.1. POORLY CHARACTERIZED SITES 285 8.1.1.
FOETAL MESENCHYME 285 8.1.2. RAT ADRENAL CORTEX AFTER NEPHRECTOMY 285
8.1.3. HYPOTHALAMUS 285 8.1.4. THE ANG (1-7) RECEPTOR 286 9.
NON-ANGIOTENSIN II RECEPTORS 287 9.1. THE /NAS-RELATED ONCOPROTEINS 287
9.2. ANG/AVP RECEPTOR 288 10. CONCLUSION 288 REFERENCES 289 CHAPTER 13
MOLECULAR BIOLOGY OF ANGIOTENSIN RECEPTORS P.A. BENFIELD AND M.H. CORJAY
1. INTRODUCTION 295 2. CLONING OF THE TYPE 1 ANGIOTENSIN II RECEPTOR 295
3. TYPE 1 RECEPTOR HETEROGENEITY 297 4. RECEPTOR STRUCTURAL ANALYSIS 300
5. COMPARISON OF THE HUMAN AND RAT SEQUENCES 301 6. IMPLICATIONS OF
STRUCTURAL FEATURES TO FUNCTION 302 6.1. LIGAND BINDING 302 6.2. SECOND
MESSENGER COUPLING 303 6.3. RECEPTOR MUTATIONAL ANALYSIS 304 7.
EXAMINATION OF RECEPTOR EXPRESSION PATTERNS 30 5 8. REGULATION OF
RECEPTOR EXPRESSION 307 XXIV 9. MOLECULAR BIOLOGY OF RELATED RECEPTORS
307 9.1. THE AT2 RECEPTOR 307 9.2. THE MAS ONCOGENE 308 9.3. SOLUBLE
ANGIOTENSIN BINDING PROTEIN 310 10. FUTURE EXPECTATIONS 310 REFERENCES
311 CHAPTER 14 FUNCTIONAL CORRELATES OF ANGIOTENSIN RECEPTOR STIMULATION
P.C. WONG AND A. F. HAJJ-ALI 1. INTRODUCTION 313 2. ANG RECEPTOR
SUBTYPES: AT1ANDAT2 313 3. HEART 317 3.1. CHRONOTROPIC ACTIONS 317 3.2.
INOTROPIC ACTIONS 318 3.3. CARDIAC HYPERTROPHIC ACTIONS 318 4. VASCULAR
SMOOTH MUSCLE 319 4.1. ARTERIAL BLOOD PRESSURE 319 4.2. REGIONAL
HEMODYNAMIC EFFECTS 321 4.3. SMOOTH MUSCLE CONTRACTION 322 4.4.
MECHANISM OF ACTION IN SMOOTH MUSCLE 322 4.5. SMOOTH MUSCLE CELL GROWTH
323 5. KIDNEY 324 5.1. RENAL VASOCONSTRICTOR EFFECT 324 5.2. RENAL
GLOMERULAR AND TUBULAR EFFECTS 325 5.3. RENAL RELEASE 327 6. NERVOUS
SYSTEM 328 6.1. CENTRAL NERVOUS SYSTEM 328 6.1.1. PRESSOR RESPONSE 328
6.1.2. DIPSOGENIC RESPONSE AND SALT APPETITE 329 6.1.3. VASOPRESSIN
SECRETION 329 6.1.4. LUTEINIZING HORMONE AND PROLACTIN SECRETION 330
6.1.5. BEHAVIOR EFFECT 330 6.2. SYMPATHETIC NERVOUS SYSTEM 331 XXV 7.
ADRENAL 332 8. MISCELLANEOUS FUNCTIONS 334 9. OTHER ANG II RECEPTOR
SUBTYPES 335 10. CONCLUSION 336 REFERENCES 338 CHAPTER 15 THE DISCOVERY
AND DESIGN OF SPECIFIC ANGIOTENSIN AT 2 RECEPTOR BINDING INHIBITORS C.J.
BLANKLEY AND I. SIRCAR 1. INTRODUCTION 347 2. AT2 SELECTIVE PEPTIDES 350
3. NONPEPTIDES 354 3.1. SPINACINES 354 3.1.1. 1 -5 ADDITIVITY 359 3.1.2.
CONSTRAINED ANALOGS 360 3.1.3. 2-SUBSTITUTION 362 3.1.4. TOOLS FOR
RECEPTOR RESEARCH 363 3.2. MIXED AT1/AT2 NONPEPTIDE ANTAGONISTS 364 3.3.
CONCLUSIONS FOR AT2 SAR 365 4. CONCLUSION 366 REFERENCES 366 CHAPTER 16
LOSARTAN POTASSIUM: CURRENT CLINICAL STATUS E.B. NELSON, C.S. SWEET, S.
SHAHINFAR AND M.R. GOLDBERG 1. INTRODUCTION 373 2. CLINICAL PHARMACOLOGY
AND PHARMACOKINETICS 374 3. CLINICAL EFFICACY 378 4. HEART FAILURE 379
5. EFFECTS ON RENAL FUNCTION 379 6. EFFECTS ON URIC ACID EXCRETION 380
7. SUMMARY 381 REFERENCES 381 XXVI CHAPTER 17 IMPROVING HYPERTENSION
TREATMENT. WHERE SHOULD WE PUT OUR EFFORTS: NEW DRUGS, NEW CONCEPTS OR
NEW MANAGEMENT? J. MENARD 1. INTRODUCTION 383 2. ARE POSITIVE RESULTS OF
CLINICAL TRIALS OVER-EMPHASIZED? 384 3. FINDING NEW DRUGS TO TREAT
HYPERTENSION 387 4. VIEWING THE SAME TARGET IN A DIFFERENT WAY 389 5.
LOOKING BEYOND THE RENIN-ANGIOTENSIN SYSTEM 390 6. CAN THE CLINICIAN
INTRODUCE BETTER MANAGEMENT 390 6.1. THE HETEROGENEITY OF BLOOD PRESSURE
RESPONSE TO DRUG THERAPY 390 6.2. DIFFICULTY OF MEASURING BLOOD PRESSURE
RESPONSE TO DRUG THERAPY 391 6.3. DIFFICULTY OF PREDICTING BLOOD
PRESSURE RESPONSE TO DRUG THERAPY 392 6.4. N OF 1 TRIAL 392 REFERENCES
394 SUBJECT INDEX 396
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV010162048 |
| callnumber-first | Q - Science |
| callnumber-label | QP609 |
| callnumber-raw | QP609.R38 |
| callnumber-search | QP609.R38 |
| callnumber-sort | QP 3609 R38 |
| callnumber-subject | QP - Physiology |
| classification_rvk | WW 8240 |
| ctrlnum | (OCoLC)488897082 (DE-599)BVBBV010162048 |
| dewey-full | 612 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 612 - Human physiology |
| dewey-raw | 612 |
| dewey-search | 612 |
| dewey-sort | 3612 |
| dewey-tens | 610 - Medicine and health |
| discipline | Biologie Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01840nam a2200457 cb4500</leader><controlfield tag="001">BV010162048</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">950428s1994 ad|| |||| 00||| engod</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0444820531</subfield><subfield code="9">0-444-82053-1</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)488897082</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV010162048</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">QP609.R38</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">612</subfield><subfield code="2">20</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">WW 8240</subfield><subfield code="0">(DE-625)152138:13423</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Medicinal chemistry of the renin-angiotensin system</subfield><subfield code="c">ed. by Pieter B. M. W. M. Timmermans ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Lausanne u.a.</subfield><subfield code="b">Elsevier</subfield><subfield code="c">1994</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXVI, 412 S.</subfield><subfield code="b">Ill., zahlr. graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Pharmacochemistry library</subfield><subfield code="v">21</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Angiotensin converting enzyme - Inhibitors - Therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Angiotensins - Physiological effect</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Angiotensins - Receptors - Antagonists</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hypertension - Chemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Renin - Inhibitors - Therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Renin - Physiological effect</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Renin-Angiotensin-System</subfield><subfield code="0">(DE-588)4177770-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Klinische Chemie</subfield><subfield code="0">(DE-588)4135255-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Renin-Angiotensin-System</subfield><subfield code="0">(DE-588)4177770-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Klinische Chemie</subfield><subfield code="0">(DE-588)4135255-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Timmermans, Pieter B.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Pharmacochemistry library</subfield><subfield code="v">21</subfield><subfield code="w">(DE-604)BV001899371</subfield><subfield code="9">21</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006748516&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-006748516</subfield></datafield></record></collection> |
| id | DE-604.BV010162048 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T17:47:33Z |
| institution | BVB |
| isbn | 0444820531 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-006748516 |
| oclc_num | 488897082 |
| open_access_boolean | |
| owner | DE-355 DE-BY-UBR |
| owner_facet | DE-355 DE-BY-UBR |
| physical | XXVI, 412 S. Ill., zahlr. graph. Darst. |
| publishDate | 1994 |
| publishDateSearch | 1994 |
| publishDateSort | 1994 |
| publisher | Elsevier |
| record_format | marc |
| series | Pharmacochemistry library |
| series2 | Pharmacochemistry library |
| spelling | Medicinal chemistry of the renin-angiotensin system ed. by Pieter B. M. W. M. Timmermans ... Lausanne u.a. Elsevier 1994 XXVI, 412 S. Ill., zahlr. graph. Darst. txt rdacontent n rdamedia nc rdacarrier Pharmacochemistry library 21 Angiotensin converting enzyme - Inhibitors - Therapeutic use Angiotensins - Physiological effect Angiotensins - Receptors - Antagonists Hypertension - Chemotherapy Renin - Inhibitors - Therapeutic use Renin - Physiological effect Renin-Angiotensin-System (DE-588)4177770-0 gnd rswk-swf Klinische Chemie (DE-588)4135255-5 gnd rswk-swf Renin-Angiotensin-System (DE-588)4177770-0 s Klinische Chemie (DE-588)4135255-5 s DE-604 Timmermans, Pieter B. Sonstige oth Pharmacochemistry library 21 (DE-604)BV001899371 21 GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006748516&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Medicinal chemistry of the renin-angiotensin system Pharmacochemistry library Angiotensin converting enzyme - Inhibitors - Therapeutic use Angiotensins - Physiological effect Angiotensins - Receptors - Antagonists Hypertension - Chemotherapy Renin - Inhibitors - Therapeutic use Renin - Physiological effect Renin-Angiotensin-System (DE-588)4177770-0 gnd Klinische Chemie (DE-588)4135255-5 gnd |
| subject_GND | (DE-588)4177770-0 (DE-588)4135255-5 |
| title | Medicinal chemistry of the renin-angiotensin system |
| title_auth | Medicinal chemistry of the renin-angiotensin system |
| title_exact_search | Medicinal chemistry of the renin-angiotensin system |
| title_full | Medicinal chemistry of the renin-angiotensin system ed. by Pieter B. M. W. M. Timmermans ... |
| title_fullStr | Medicinal chemistry of the renin-angiotensin system ed. by Pieter B. M. W. M. Timmermans ... |
| title_full_unstemmed | Medicinal chemistry of the renin-angiotensin system ed. by Pieter B. M. W. M. Timmermans ... |
| title_short | Medicinal chemistry of the renin-angiotensin system |
| title_sort | medicinal chemistry of the renin angiotensin system |
| topic | Angiotensin converting enzyme - Inhibitors - Therapeutic use Angiotensins - Physiological effect Angiotensins - Receptors - Antagonists Hypertension - Chemotherapy Renin - Inhibitors - Therapeutic use Renin - Physiological effect Renin-Angiotensin-System (DE-588)4177770-0 gnd Klinische Chemie (DE-588)4135255-5 gnd |
| topic_facet | Angiotensin converting enzyme - Inhibitors - Therapeutic use Angiotensins - Physiological effect Angiotensins - Receptors - Antagonists Hypertension - Chemotherapy Renin - Inhibitors - Therapeutic use Renin - Physiological effect Renin-Angiotensin-System Klinische Chemie |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=006748516&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV001899371 |
| work_keys_str_mv | AT timmermanspieterb medicinalchemistryofthereninangiotensinsystem |